Beijing Tiantan Biological Products Co., Ltd. (SHA: 600161)

China flag China · Delayed Price · Currency is CNY
22.80
+0.14 (0.62%)
Nov 12, 2024, 3:00 PM CST
-8.03%
Market Cap 44.73B
Revenue (ttm) 5.23B
Net Income (ttm) 1.27B
Shares Out 1.98B
EPS (ttm) 0.64
PE Ratio 35.46
Forward PE 32.53
Dividend 0.13 (0.55%)
Ex-Dividend Date Jun 20, 2024
Volume 32,321,659
Open 22.68
Previous Close 22.66
Day's Range 22.62 - 23.27
52-Week Range 20.17 - 27.60
Beta 0.31
Analysts n/a
Price Target n/a
Earnings Date Oct 25, 2024

About Beijing Tiantan Biological Products

Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and consulting of blood products in China. Its products include human albumin; intravenous human immunoglobulin; tetanus human immunoglobulin; rabies patient immunoglobulin; hepatitis B human immunoglobulin; freeze-dried intravenous hepatitis B human immunoglobulin; and human prothrombin complex blood products. The company was founded in 1919 and is headquartered in Beijing, China. Beijing Tiantan Biological Products Co., Ltd. is a subsidia... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1919
Employees 4,858
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 600161
Full Company Profile

Financial Performance

In 2023, Beijing Tiantan Biological Products's revenue was 5.18 billion, an increase of 21.57% compared to the previous year's 4.26 billion. Earnings were 1.11 billion, an increase of 25.99%.

Financial Statements

News

There is no news available yet.